Page 15 - Mesenchymal Stem cells, Exosomes and vitamins in the fight aginst COVID

Pain Physician: March/April 2020: 23:E71-E83

Burden of diseases, injuries, and risk respiratory syndrome coronavirus clinical studies. Biosci Trends 2020; 14:72-
factors. JAMA 2013; 310:591-608. infection. Antimicrob Agents Chemother 73.
15. Dieleman JL, Cao J, Chapin A, et al. 2014; 58:4885-4893. 40. Centers for Disease Control and
US health care spending by payer and 29. Mire CE, Geisbert JB, Agans KN, et al. Prevention. Evaluating and Testing
health condition, 1996-2016. JAMA 2020; Passive Immunotherapy: Assessment Persons for Coronavirus Disease 2019
323:863-884. of convalescent serum against Ebola (COVID-19).
16. Cascella M, Rajnik M, Cuomo A, Virus Makona Infection in nonhuman www.cdc.gov/coronavirus/2019-ncov/
Dulebohn SC, Di Napoli R. Features, primates. J Infect Dis 2016; 214: hcp/clinical-criteria.html
Evaluation and Treatment Coronavirus S367-S374. 41. Celltex Plans to Launch Program to Use
(COVID-19). StatPearls [Internet]. 30. Marano G, Vaglio S, Pupella S, et al. Mesenchymal Stem Cells for COVID-
Treasure Island (FL): StatPearls Publishing; Convalescent plasma: new evidence for 19-related Symptoms Under an Existing
2020 Jan-.2020 Mar 8. an old therapeutic tool? Blood Transfus Regulatory Study. Business Wire, March
17. Huang C, Wang Y, Li X, et al. Clinical 2016; 14:152-157. 16, 2020. Accessed date 3/18/2020.
features of patients infected with 2019 31. Karakus U, Pohl MO, Stertz S. Breaking www.businesswire .com/news/
novel coronavirus in Wuhan, China. the convention: Sialoglycan variants, co- home/20200316005852/en/Celltex-
Lancet 2020; 395:497-506. receptors and alternative receptors for Plans-Launch-Program-Mesenchymal-
18. Tortorici MA, Veesler D. Structural influenza a virus entry. J Virol 2019; 94:4. Stem-Cells.
insights into coronavirus entry. Adv Virus 32. Wong SK, Li W, Moore MJ, et al. A 42. MedicalXpress Breaking News and
Res 2019; 105:93-116. 193-amino acid fragment of the SARS Events. Coronavirus drugs: Who’s doing
19. Casadevall A, Pirofski LA. The Ebola coronavirus S protein efficiently binds what, and when they might come. March
epidemic crystallizes the potential of angiotensin-converting enzyme 2. J Biol 17, 2020. Accessed date 3/18/2020.
passive antibody therapy for infectious Chem 2004; 279:3197-3201. www .mdlinx.com/pain -
diseases. PLoS Pathog 2015; 11:e1004717. 33. Li W, Moore MJ, Vasilieva N, et al. management/top-medical-news/
20. Shin YW, Chang KH, Hong GW, et al. Angiotensin-converting enzyme 2 is article/index.cfm/?publish_dt=03-
Selection of vaccinia virus-neutralizing a functional receptor for the SARS 1 7 - 2 0 2 0 & r o w N u m = 7 6 2 1 3 9 3 & _
antibody from a phage-display human- coronavirus. Nature 2003; 426:450-454. rw=true&utm_source=alert&utm_
antibody library. J Microbiol Biotechnol 34. Yao X, Ye F, Zhang M, et al. In vitro medium=email&utm_
2019; 29:651-657. antiviral activity and projection campaign=ajm_49664&
21. Keck ZY, Wang Y, Lau P, et al. Isolation of optimized dosing design of 43. Kimera Exosomes. (MSC) Exosome
of HCV neutralizing antibodies by yeast hydroxychloroquine for the treat ment Laboratory. Accessed date 3/19/2020.
display. Methods Mol Biol 2019; 1911:395- of Severe Acute Respiratory Syndrome www.kimeralabs.com/
419. Coronavirus 2 (SARS-CoV-2). Clin Infect
Dis. 2020 Mar 9. [Epub ahead of print] 44. Centers for Disease Control and
22. Tsai CH, Lee PY, Stollar V, et al. Antiviral Prevention. Interim Guidance for
therapy targeting viral polymerase. Curr 35. Multicenter collaboration group of Healthcare Facilities: Preparing for
Pharm Des 2006; 12:1339-1355. Department of Science and Technology Community Transmission of COVID-19
of Guangdong Province and Health
23. Anderson J, Schiffer C, Lee SK, et al. in the United States.
Viral protease inhibitors. Handb Exp Commission of Guangdong Province www.cdc.gov/coronavirus/2019-ncov/
Pharmacol 2009; 189:85-110. for chloroquine in the treatment of healthcare-facilities/guidance-hcf.html
24. Litterman N, Lipinski C, Ekins S. Small novel coronavirus pneumonia. Expert Accessed date 3/18/2020.
consensus on chloroquine phosphate
molecules with antiviral activity against for the treatment of novel coronavirus 45. Knoepfler P. ‘We Cannot Stick to the
the Ebola virus [version 1; peer review: 2 pneumonia. Zhonghua Jie He He Hu Xi Za Rules’: claims of stem cells saving
approved]. F1000Res 2015; 4:38.
Zhi 2020; 43:185-188. COVID-19 patients. The Niche, March 3,
25. Dodd LE, Follmann D, Proschan M, et 36. Li H, Wang YM, Xu JY, Cao B. Potential 2020.
al. A meta-analysis of clinical studies antiviral therapeutics for 2019 Novel https://ipscell.com/2020/03/we-cannot-
conducted during the West Africa Ebola Coronavirus. Zhonghua Jie He He Hu Xi stick-to-the-rules-claims-of-stem-cells-
virus disease outbreak confirms the Za Zhi 2020; 43:170-172. saving-covid-19-patients/
need for randomized control groups. Sci 46. Centers for Disease Control and
Transl Med 2019; 11:520. 37. Wang M, Cao R, Zhang L, et al. Prevention. Coronavirus Pandemic
26. Sheahan TP, Sims AC, Leist SR, et al. Remdesivir and chloroquine effectively Update 37: The ACE-2 Receptor - The
inhibit the recently emerged novel
Comparative therapeutic efficacy of coronavirus (2019-nCoV) in vitro. Cell Doorway to COVID-19 (ACE Inhibitors &
remdesivir and combination lopinavir, Res 2020; 30:269-271. ARBs). Accessed date 3/18/2020.
ritonavir, and interferon beta against www.youtube.com/watch?v=1vZDVbqR
MERS-CoV. Nat Commun 2020; 11: 222. 38. Vincent MJ, Bergerson E, Benjannet S, hyM&feature=youtu.be&fbclid=IwAR3X
27. Li CC, Wang XJ, Wang HR: Repurposing et al. Chloroquine is a potent inhibitor ZZZZmzSk7ltqNuZ5mM19MxRkiv6fhfs
of SARS coronavirus infection and
host-based therapeutics to control spread. Virol J 2005; 2:69. NB1LjAR1qte7wmeUXs-vI45U
coronavirus and influenza virus. Drug 47. Xu X, Chen P, Wang J, et al. Evolution of
Discov Today 2019; 24:726-736. 39. Gao J, Tian Z, Yang X. Breakthrough:
Chloroquine phosphate has shown the novel coronavirus from the ongoing
28. Dyall J, Coleman CM, Hart BJ, et al. apparent efficacy in treatment of Wuhan outbreak and modeling of
Repurposing of clinically developed COVID-19 associated pneumonia in its spike protein for risk of human
drugs for treatment of Middle East transmission. Sci China Life Sci 2020;
E80 www.painphysicianjournal.com